Allogene Overland Appoints Shuyuan Yao as CEO
On Monday, June 21, Allogene announced (press release) that Shuyuan Yao has been appointed as CEO of Allogene Overland Biopharm. Below, Celltelligence provides insights on how Shuyuan Yao’s vast cell therapy experience could position Allogene Overland for rapid growth in Greater China and throughout the Asia-Pacific region.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.